12/26
04:51 am
enta
Antibiotic Resistance Therapeutics Market Research Report 2025-2029 - Search for Alternatives to Antibiotics Creates New Global Goldrush [Yahoo! Finance]
Neutral
Report
Antibiotic Resistance Therapeutics Market Research Report 2025-2029 - Search for Alternatives to Antibiotics Creates New Global Goldrush [Yahoo! Finance]
12/24
08:14 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.
12/24
07:00 am
enta
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
Neutral
Report
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
12/23
11:16 am
enta
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? [Yahoo! Finance]
12/9
06:30 am
enta
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Low
Report
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
12/6
05:02 pm
enta
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) [Yahoo! Finance]
High
Report
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) [Yahoo! Finance]
12/6
05:00 pm
enta
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
High
Report
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
11/29
01:00 am
enta
Enanta Pharmaceuticals' Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals' Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility [Yahoo! Finance]
11/26
11:19 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at Robert W. Baird from $26.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at Robert W. Baird from $26.00 to $20.00. They now have an "outperform" rating on the stock.
11/26
08:00 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock, down previously from $22.00.
Medium
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock, down previously from $22.00.
11/25
06:48 pm
enta
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/25
04:16 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 [Yahoo! Finance]
11/25
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Medium
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
10/27
09:06 am
enta
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable [Yahoo! Finance]
Low
Report
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable [Yahoo! Finance]
10/10
08:40 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
10/9
02:40 pm
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
10/2
09:47 am
enta
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
9/27
11:05 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
Medium
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.